Qube Research & Technologies (QRT)
AZN icon

Qube Research & Technologies (QRT)’s AstraZeneca AZN Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$71.2M Sell
375,473
-6,575
-2% -$1.24M 0.07% 382
2026
Q1 		$75.3M Buy
+382,048
New +$73.7M 0.08% 293
2025
Q4 		– Sell
-387,202
Closed -$67.9M – 3670
2025
Q3 		$59.4M Buy
387,202
+52,143
+16% +$7.89M 0.06% 397
2025
Q2 		$46.8M Buy
335,059
+223,244
+200% +$31.3M 0.05% 498
2025
Q1 		$16.4M Sell
111,815
-183,456
-62% -$26.5M 0.02% 847
2024
Q4 		$38.7M Sell
295,271
-156,435
-35% -$21.9M 0.05% 468
2024
Q3 		$70.4M Buy
451,706
+438,354
+3,283% +$70.8M 0.1% 243
2024
Q2 		$2.08M Sell
13,352
-30,439
-70% -$4.58M ﹤0.01% 1603
2024
Q1 		$5.93M Sell
43,791
-439,736
-91% -$58.2M 0.01% 1135
2023
Q4 		$65.1M Buy
483,527
+447,799
+1,253% +$58.2M 0.13% 200
2023
Q3 		$4.84M Sell
35,728
-251,207
-88% -$34.3M 0.01% 946
2023
Q2 		$41.1M Buy
286,935
+37,095
+15% +$5.46M 0.15% 193
2023
Q1 		$34.7M Buy
249,840
+8,892
+4% +$1.2M 0.15% 152
2022
Q4 		$32.7M Buy
240,948
+63,336
+36% +$7.94M 0.17% 143
2022
Q3 		$19.5M Buy
+177,612
New +$22.5M 0.12% 244
2020
Q4 		– Sell
-53,575
Closed -$5.87M – 1802
2020
Q3 		$5.87M Sell
53,575
-3,948
-7% -$439K 0.08% 308
2020
Q2 		$6.08M Buy
+57,523
New +$5.94M 0.09% 288
2020
Q1 		– Sell
-25,139
Closed -$2.51M – 1130
2019
Q4 		$2.51M Buy
25,139
+17,859
+245% +$1.68M 0.08% 301
2019
Q3 		$649K Buy
+7,280
New +$631K 0.43% 68
2018
Q2 		– Sell
-3,594
Closed -$251K – 834
2018
Q1 		$251K Buy
+3,594
New +$249K 0.1% 132

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Qube Research & Technologies (QRT)'s AZN Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its AstraZeneca (AZN) stake by 1.7% in Q2 2026, selling an estimated $1.24M and leaving 375,473 shares worth $71.2M. The position accounts for 0.07% of the portfolio, ranked #382.

Qube Research & Technologies (QRT) first reported a position in AZN in Q1 2018 and has held it in 20 quarters since. The position peaked at $75.3M in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Qube Research & Technologies (QRT) held 375,473 shares of AstraZeneca worth $71.2M as of Q2 2026.
  • Qube Research & Technologies (QRT) sold 6,575 AstraZeneca shares in Q2 2026, an estimated $1.24M.
  • AstraZeneca made up 0.07% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #382 holding.
  • Qube Research & Technologies (QRT) first reported a position in AstraZeneca in Q1 2018 and has held it in 20 quarters since.
  • Qube Research & Technologies (QRT)'s AstraZeneca position peaked at $75.3M in Q1 2026.
  • 1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.